Suppr超能文献

颅底脊索瘤的预后因素:一项系统文献综述与荟萃分析

Prognostic Factors in Skull Base Chordoma: A Systematic Literature Review and Meta-Analysis.

作者信息

Zou Ming-Xiang, Lv Guo-Hua, Zhang Qian-Shi, Wang Shao-Fu, Li Jing, Wang Xiao-Bin

机构信息

Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.

Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.

出版信息

World Neurosurg. 2018 Jan;109:307-327. doi: 10.1016/j.wneu.2017.10.010. Epub 2017 Oct 16.

Abstract

OBJECTIVE

Currently, there are a lack of reviews assessing the complete range of prognostic factors in skull base chordoma (SBC). This study aimed to systematically review the published literature on prognostic factors in SBC and establish pooled hazard ratios (HRs) of such factors.

METHODS

MEDLINE and Embase searches (inception to April 4, 2017) were conducted. Two reviewers independently selected papers involving SBC prognostic factors, and studied them for methodologic quality and valuable factors. Pooled HRs and 95% confidence intervals (CIs) were calculated. The main end points determined were progression-free survival (PFS) and overall survival (OS).

RESULTS

Twenty-two studies with 1754 subjects were included in this systematic review. However, only 18 of the studies provided sufficient data for quantitative synthesis. Preoperative visual deficit (pooled HR, 2.77; 95% CI, 1.57-4.89 for PFS), older patient age (pooled HR, 1.03; 95% CI, 1.1-1.05 for PFS; pooled HR, 1.03; 95% CI, 1.2-1.04 for OS), and nontotal or intralesional tumor resection (pooled HR, 2.01; 95% CI, 1.54-2.62 for PFS; pooled HR, 5.16; 95% CI, 2.27-11.70 for OS) were negative predictors of survival outcomes. However, adjunctive radiotherapy (pooled HR, 0.30; 95% CI, 0.16-0.56) and chondroid chordoma type (pooled HR, 0.5; 95% CI, 0.36-0.69) portended a favorable PFS. In addition, several prognostic biomarkers were promising.

CONCLUSIONS

This study demonstrated that several clinicopathologic or molecular parameters are associated with survival up to tumor progression or mortality in SBC patients. However, further methodologically high-quality reports are still required to clarify the effects of these factors.

摘要

目的

目前,缺乏对颅底脊索瘤(SBC)所有预后因素的评估综述。本研究旨在系统回顾已发表的关于SBC预后因素的文献,并确定这些因素的合并风险比(HRs)。

方法

进行了MEDLINE和Embase检索(起始至2017年4月4日)。两名审阅者独立挑选涉及SBC预后因素的论文,并研究其方法学质量和有价值的因素。计算合并HRs和95%置信区间(CIs)。确定的主要终点为无进展生存期(PFS)和总生存期(OS)。

结果

本系统综述纳入了22项研究,共1754名受试者。然而,只有18项研究提供了足够的数据用于定量综合分析。术前视力障碍(PFS的合并HR为2.77;95%CI为1.57 - 4.89)、患者年龄较大(PFS的合并HR为1.03;95%CI为1.1 - 1.05;OS的合并HR为1.03;95%CI为1.2 - 1.04)以及肿瘤未全切除或瘤内切除(PFS的合并HR为2.01;95%CI为1.54 - 2.62;OS的合并HR为5.16;95%CI为2.27 - 11.70)是生存结局的负性预测因素。然而,辅助放疗(合并HR为0.30;95%CI为0.16 - 0.56)和软骨样脊索瘤类型(合并HR为0.5;95%CI为0.36 - 0.69)预示着较好的PFS。此外,一些预后生物标志物很有前景。

结论

本研究表明,一些临床病理或分子参数与SBC患者直至肿瘤进展或死亡的生存期相关。然而,仍需要进一步的方法学高质量报告来阐明这些因素的影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验